CO5190694A1 - Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos - Google Patents

Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos

Info

Publication number
CO5190694A1
CO5190694A1 CO00065517A CO00065517A CO5190694A1 CO 5190694 A1 CO5190694 A1 CO 5190694A1 CO 00065517 A CO00065517 A CO 00065517A CO 00065517 A CO00065517 A CO 00065517A CO 5190694 A1 CO5190694 A1 CO 5190694A1
Authority
CO
Colombia
Prior art keywords
progesterone
mcphail
mesoprogestins
female
contraception
Prior art date
Application number
CO00065517A
Other languages
English (en)
Spanish (es)
Inventor
Walter Elger
Chwalisz Kristof
Gerd Schubert
Original Assignee
Jenapharm Gmbh And Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh And Co Kg filed Critical Jenapharm Gmbh And Co Kg
Publication of CO5190694A1 publication Critical patent/CO5190694A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO00065517A 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos CO5190694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
CO5190694A1 true CO5190694A1 (es) 2002-08-29

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00065517A CO5190694A1 (es) 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos

Country Status (28)

Country Link
EP (1) EP1605949A2 (no)
JP (1) JP2003511399A (no)
KR (1) KR20020038745A (no)
CN (1) CN1384748A (no)
AR (1) AR025455A1 (no)
AU (1) AU781835B2 (no)
BG (1) BG106441A (no)
BR (1) BR0013711A (no)
CA (1) CA2383650A1 (no)
CO (1) CO5190694A1 (no)
CZ (1) CZ2002707A3 (no)
EA (1) EA006805B1 (no)
EE (1) EE200200103A (no)
HR (1) HRP20020265A2 (no)
HU (1) HUP0202515A3 (no)
IL (1) IL148415A0 (no)
LT (1) LT5001B (no)
LV (1) LV12940B (no)
MX (1) MXPA02002186A (no)
NO (1) NO20020998L (no)
NZ (1) NZ517470A (no)
PE (1) PE20010579A1 (no)
PL (1) PL353994A1 (no)
SI (1) SI20853A (no)
SK (1) SK2982002A3 (no)
UA (1) UA77150C2 (no)
WO (1) WO2001026603A2 (no)
YU (1) YU13902A (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50304970D1 (de) * 2002-08-02 2006-10-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
CA2571377C (en) * 2004-07-07 2014-03-25 Wyeth Cyclic progestin regimens and kits
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
PL2419108T3 (pl) 2009-04-14 2017-08-31 Laboratoire Hra Pharma Sposób antykoncepcji na żądanie
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
FI101601B (fi) * 1987-09-24 1998-07-31 Jencap Res Ltd Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmist een valmistusmenetelmässä
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AU707235B2 (en) * 1994-10-24 1999-07-08 Schering Aktiengesellschaft Competitive progesterone antagonists for demand-oriented female birth control
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
KR20000022189A (ko) * 1996-06-25 2000-04-25 에프.지.엠. 헤르만스;이.에이치. 리링크 프로제스토젠-항프로제스토젠 섭생
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
CN1353717A (zh) * 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法

Also Published As

Publication number Publication date
CZ2002707A3 (cs) 2002-11-13
BR0013711A (pt) 2002-05-07
SI20853A (sl) 2002-10-31
WO2001026603A2 (en) 2001-04-19
BG106441A (bg) 2002-09-30
EA006805B1 (ru) 2006-04-28
CN1384748A (zh) 2002-12-11
YU13902A (sh) 2006-01-16
HUP0202515A3 (en) 2004-06-28
HUP0202515A2 (hu) 2002-12-28
EE200200103A (et) 2003-04-15
PE20010579A1 (es) 2001-06-04
AR025455A1 (es) 2002-11-27
LT2002035A (lt) 2002-10-25
UA77150C2 (en) 2006-11-15
NO20020998L (no) 2002-03-14
WO2001026603A3 (en) 2002-01-17
MXPA02002186A (es) 2002-09-02
PL353994A1 (en) 2003-12-15
LV12940B (en) 2003-06-20
EA200200284A1 (ru) 2002-10-31
LT5001B (lt) 2003-03-25
AU781835B2 (en) 2005-06-16
NZ517470A (en) 2004-03-26
EP1605949A2 (en) 2005-12-21
CA2383650A1 (en) 2001-04-19
NO20020998D0 (no) 2002-02-28
HRP20020265A2 (en) 2004-02-29
IL148415A0 (en) 2002-09-12
AU3215001A (en) 2001-04-23
KR20020038745A (ko) 2002-05-23
SK2982002A3 (en) 2002-07-02
JP2003511399A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
US7833545B2 (en) Methods and devices for the sustained release of multiple drugs
US7871995B2 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
Bertschinger et al. Induction of contraception in some African wild carnivores by downregulation of LH and FSH secretion using the GnRH analogue deslorelin
PT87053A (pt) Processo para a preparacao de composicoes contraceptivas contendo meletonina e metodo para efectuar a contracepcao
RU2005140277A (ru) Система доставки лекарственного вещества
ATE302790T1 (de) 8beta-substituierte-11beta-pentyl-und 11beta- hexyl-estra-1,3,5(10)-trienderivate
EA200000492A1 (ru) Пероральные контрацептивы, содержащие антиэстроген плюс прогестин
CO5261567A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas
CO5190694A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos
ECSP055530A (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
CO5200772A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes
CO5200773A1 (es) Mesoprogestinas (moduladores de receptores para progestero- na) como componente de composiciones utilizadas para la terapia de sustitucion hormonal (trh)
Hahn et al. The pharmacological profile of norgestimate, a new orally active progestin
Simon et al. Polysiloxane vaginal rings and cylinders for physiologic endometrial priming in functionally agonadal women
AU692150B2 (en) Method of preventing or inhibiting fertilization
Mehrotra et al. Emetine ditartrate: a possible lead for emergency contraception
Peplow et al. An intrauterine silastic system for the sustained release of indomethacin
Kesler Remotely delivered contraception with needle-less norgestomet implants
Pathak et al. Non-steroidal antifertility agents
Yokoyama et al. Alopecia related to low dose oral contraceptive
Pendergrass et al. The effect of an H1 blocker, chlorpheniramine maleate, on total menstrual loss
World Health Organization Estudios recientes sobre regulaci'on de la fecundidad: informe de un Grupo Cient'ifico de la OMS [se reunió en Ginebra del 11 al 15 de noviembre de 1968]
BR0010070A (pt) Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio
UY26967A1 (es) Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.-

Legal Events

Date Code Title Description
FC Application refused